NCT06573138

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in the Treatment of Relapsed or Refractory Natural Killer / T-cell Lymphoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 14 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.

Detailed description

This study aims to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in relapsed or refractory NKTCL and find the optimal treatment regimen for patients with relapsed refractory NKTCL. Patients receive 3 cycles of Selinexor, anti-PD-1 antibody plus Golidocitinib and then PET evaluation.

Conditions

• Lymphoma, Extranodal NK-T-Cell

Interventions

Type	Name	Description
DRUG	Selinexor, anti-PD-1 antibody plus Golidocitinib	Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.

Timeline

• Start date: 2024-09-01
• Primary completion: 2027-07-01
• Completion: 2027-07-01
• First posted: 2024-08-27
• Last updated: 2024-08-27